Screening for Primary Ciliary Dyskinesia Using Nasal Nitric Oxide

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by Ziv Hospital.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Ziv Hospital
ClinicalTrials.gov Identifier:
NCT00739817
First received: August 21, 2008
Last updated: August 15, 2009
Last verified: August 2009
  Purpose

Background: Primary ciliary dyskinesia (PCD) is a rare genetic disease characterised by recurrent respiratory infections and subfertility due to dysfunction of cilia (brushes) of the lining cells. Undiagnosed and untreated it can result in an irreversible crippling chronic lung disease. The diagnosis of PCD is a difficult one and involves the complex assessment of ciliary structure and function. Thus, PCD is under diagnosed and appropriate preventative and symptomatic treatment may be denied in many patients. In addition, the gene responsible for PCD is at present unknown, thus preventing pre-natal diagnosis and genetic counseling.

Working hypothesis and aims: Recently, it has become apparent that the evaluation of nasally expired nitric oxide (NO) constitutes a simple and non-invasive diagnostic method, which discriminates between PCD patients, PCD carriers and healthy controls at high rate of specificity and sensitivity. Testing is simple and last approximately one minute. We have recently identified a unique isolated Druze population with high prevalence of PCD. The high frequency of disease places this closed community at a high risk of undiagnosed PCD.

The aim of this project is to use nasal NO measurement as a screening tool to identify possible undiagnosed cases of PCD and PCD carriers in this high risk Druze population.


Condition
Primary Ciliary Dyskinesia

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Screening for Primary Ciliary Dyskinesia Using Nasal Nitric Oxide

Resource links provided by NLM:


Further study details as provided by Ziv Hospital:

Primary Outcome Measures:
  • Nasal NO < 105 ppb [ Time Frame: at enrollment ] [ Designated as safety issue: No ]

Estimated Enrollment: 6000
Study Start Date: July 2010
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

community

Criteria

Inclusion Criteria:

  • Voluntary willing to participate

Exclusion Criteria:

  • Recent URTI
  • Steroids use 2 weeks prior to testing
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00739817

Contacts
Contact: Israel Amirav, MD 97246828712 amirav@012.net.il

Locations
Israel
Pediatric Department, Ziv Medical Center Not yet recruiting
Safed, Israel
Contact: Israel Amirav, MD    9726828712    amirav@012.net.il   
Sponsors and Collaborators
Ziv Hospital
  More Information

No publications provided

Responsible Party: Israel Amirav, Ziv Medical center
ClinicalTrials.gov Identifier: NCT00739817     History of Changes
Other Study ID Numbers: HP-6-199-R
Study First Received: August 21, 2008
Last Updated: August 15, 2009
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Ciliary Motility Disorders
Kartagener Syndrome
Dyskinesias
Respiratory Tract Diseases
Otorhinolaryngologic Diseases
Bronchiectasis
Bronchial Diseases
Respiratory System Abnormalities
Dextrocardia
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities
Situs Inversus
Genetic Diseases, Inborn
Movement Disorders
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Nitric Oxide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 23, 2014